AbelZeta Pharma
PrivateLast Round
Series A
Sep 30, 2021
Total Funding Raised
$120M
Company Overview
AbelZeta Pharma operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a Series A round in September 2021.
AbelZeta Pharma is a biopharmaceutical company that focuses on developing innovative and proprietary cell-based therapeutic products to treat hematological malignancies, solid tumors, and inflammatory and immunological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AbelZeta Pharma Comparables
Compare AbelZeta Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PersonGen BioTherapeutics | 84% | |
| Oricell Therapeutics | 84% | |
| Shanghai YaKe Biotechnology Co., Ltd. | 82% |
For institutional investors. Book with your work email.
AbelZeta Pharma Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
AbelZeta Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GIC Private Limited | Series A |
| CICC Capital | Series A |
| Yunfeng Capital | Series A |
| HongShan Capital Group (HSG) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 15, 2024
Monthly visitors grew 33% MoM, reaching 2.4K.
- Oct 30, 2024
Monthly visitors increased 80% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 9, 2026
AbelZeta Pharma, Inc. presents updated Phase I results for C-CAR031 (AZD7003) in advanced hepatocellular carcinoma at ESMO Congress 2026 in Spain on Oct 26th '26.
- attends_eventNov 9, 2026
AbelZeta Pharma, Inc. presents updated clinical results from the first-in-human study of AZD7003 in advanced hepatocellular carcinoma at the European Society for Medical Oncology (ESMO) Congress 2026 in Spain on Oct 26th '26.
For institutional investors. Book with your work email.
AbelZeta Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AbelZeta Pharma's valuation, stock price, and market status.
Is AbelZeta Pharma a public or private company?
AbelZeta Pharma is a private company.
What is the current stock price of AbelZeta Pharma?
AbelZeta Pharma is a private company, so its shares have no public market price. Caplight tracks AbelZeta Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AbelZeta Pharma worth (valuation)?
Valuation information for AbelZeta Pharma is not publicly available.
Can I buy AbelZeta Pharma stock?
AbelZeta Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AbelZeta Pharma's last funding round?
AbelZeta Pharma's most recent funding round was Series A on September 30, 2021.
Who are the main investors in AbelZeta Pharma?
Key investors in AbelZeta Pharma include CICC Capital, Yunfeng Capital, HongShan Capital Group (HSG).
Will AbelZeta Pharma IPO soon?
No public IPO plans have been announced for AbelZeta Pharma.
How can I track AbelZeta Pharma secondary market activity?
Caplight tracks bids, offers, and trades in AbelZeta Pharma's shares on secondary markets.